UroGen Pharma Ltd. (URGN) › Cost of RevenueUroGen Pharma Ltd. (URGN) — Cost of RevenueAnnual figures by period end, from SEC filings.2016-12-31: $28.0K2017-12-31: $600.0K2018-12-31: $1.80M2020-12-31: $1.01M2021-12-31: $5.16M2022-12-31: $7.65M2023-12-31: $9.36M2024-12-31: $8.88M2025-12-31: $12.45M$12.45M2016-12-31Cost of Revenue (USD)2025-12-31Period endedCost of RevenueChange YoYSource filing2025-12-31$12.45M+40.2%2026-03-02From 2025-01-012024-12-31$8.88M-5.1%2026-03-02From 2024-01-012023-12-31$9.36M+22.3%2025-03-10From 2023-01-012022-12-31$7.65M+48.4%2024-03-14From 2022-01-012021-12-31$5.16M+411.1%2023-03-24From 2021-01-012020-12-31$1.01M—2022-03-21From 2020-01-012018-12-31$1.80M+200.5%2020-03-02From 2018-01-012017-12-31$600.0K+2042.9%2020-03-02From 2017-01-012016-12-31$28.0K—2019-02-28From 2016-01-01Other metrics: RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)